Browse Articles
Discover research articles across all indexed journals
Cross resistance among novel androgen receptor axis-targeted agents in non-metastatic castration-resistant prostate cancer: A multi-institutional retrospective study.
395 Background: Previous studies reported a cross resistance among novel androgen receptor axis-targeted agents (ARATs) in patients with metastatic castration-resistant prostate cancer. However, the effects of sequential therapy with novel ARATs in non-metastatic castration-resistant prostate cancer (nmCRPC) remain unclear. Methods: This multi-institutional retrospective study included 56 patients with nmCRPC treated with second-novel ARATs after first-novel ARATs treatments, including apalutamide, enzalutamide, darolutamide, and abiraterone acetate between January 2014 and April 2024. The duration of novel ARATs treatment and PSA response were compared between first-use and second-use of novel ARATs. Results: The median age at nmCRPC diagnosis were 76 years. Of the 56 patients, 14 (25%), 16 (29%), 11 (20%), and 16 (29%) were treated with apalutamide, enzalutamide, darolutamide, and abiraterone acetate as second-novel ARATs. Median duration of novel ARATs treatment in second-use was significantly shorter than that in first-use (7.0 month vs. 14 month, respectively, P = 0.038). The rates of PSA decline ≥50% and ≥90% in second-use were significantly lower than those in first-use (25% vs. 73%, P < 0.001; 9.1% vs. 36%, P = 0.004; respectively). The rate of patients who did not achieve any PSA response in second-use was significantly higher than that in first-line use (45% vs. 11%, P < 0.001). Conclusions: A significant cross resistance among novel ARATs was observed in patients with nmCRPC. A further study is needed to evaluate the optimal candidates for sequential therapy with novel ARATs.
Association between sociodemographic marginalization and receipt of intensified treatment for metastatic castrate-sensitive prostate cancer.
96 Background: Intensified treatment beyond androgen deprivation therapy (ADT) has been shown to improve survival in patients with metastatic castrate-sensitive prostate cancer (mCSPC). However, real-world utilization remains inadequate. To assess potential differential access to such life-prolonging treatments, we assessed the association between sociodemographic marginalization and receipt of intensified treatment in patients newly diagnosed with mCSPC within a universal healthcare system. Methods: We performed a population-based cohort study of men aged 66 years or older diagnosed with de novo mCSPC in Ontario, Canada from Jan 2014-Nov 2021. Hierarchical regression models adjusting for patient, tumor, and physician characteristics were used to estimate odds ratios (OR) and 95% confidence intervals (CI) for the association between patient marginalization, measured by the Ontario Marginalization Index (ON-MARG), and receipt of intensified treatment, within 6 months of diagnosis. ON-MARG, a validated measure created using Canadian census data, provides area-level measures of marginalization in four domains: (1) households and dwellings; (2) material resources; (3) age and labour force; and (4) racialized and newcomer populations. Results: Among 6,051 patients, 1,465 (24%) received intensified treatment. Higher levels of composite marginalization were associated with a lower likelihood of receiving intensified treatment (OR 0.91, 95% CI 0.83–0.99, p=0.03). When examining individual domains of marginalization (Table 1), the racialized and newcomer populations domain showed the strongest negative association with the receipt of intensified treatment (OR 0.89, 95% CI 0.81–0.97, p=0.01). Conclusions: Sociodemographic marginalization, particularly among racialized and newcomer populations, is associated with lower rates of intensified treatment in patients with de novo mCSPC, even within a universal healthcare system, further contributing to known disparities in prostate cancer outcomes. Association between ON-MARG domains and treatment intensification among patients with de novo mCSPC in adjusted models.* ON-MARG Domain Effect Estimate (95% CI) Households & Dwellings OR 0.92 (0.85-0.98), p=0.02 Material Resources OR 0.93, (0.86-0.99), p=0.03 Age & Labour Force OR 0.99, (0.94-1.04), p=0.65 Racialized & Newcomer Populations OR 0.89, (0.81-0.97), p=0.01 *Each ON-MARG Domain was modelled in separate multivariable models adjusting for patient characteristics including age at diagnosis, Charlson comorbidity category, and area; tumor characteristics including Gleason score at diagnosis; as well as physician age, sex, years in practice, specialty, and group volume.
Design guidelines for Si metal–oxide–semiconductor and Si/SiGe heterostructure quantum dots for spin qubits
Si-based spin qubits are promising due to their long decoherence time and the compatibility with state-of-the-art semiconductor technology and have been demonstrated using quantum dots (QDs) to host single electrons for spin manipulation. In this work, we simulate the electrostatics and quantum transport properties of quantum dots on a Si metal–oxide–semiconductor platform and a Si/SiGe heterostructure. We investigate the effects of gate configurations and the SiGe spacer thickness on device characteristics, such as gate capacitances, Coulomb blockade, and charge stability. For a single quantum dot, placing its barrier gates (BGs) under the plunger gate improves the charge stability, while swapping the positions of those gates reduces the effects of the barrier gate biases on the charge stability. A thicker SiGe spacer further suppresses the effects of the barrier gate biases on the charge stability for quantum dots on the Si/SiGe heterostructure but leads to stronger crosstalk between neighboring quantum dots. Wider barrier gates can help to mitigate the crosstalk effects for multiple quantum dots. These findings provide key insights into the optimization of the gate configurations and material selection to improve the charge stability and minimize the crosstalk by different gates for future development of scalable Si-based quantum dots.
Author Correction: Follistatin like-1 aggravates silica-induced mouse lung injury
Trends in inpatient outcomes of bladder cancer: 2008-2021.
674 Background: Bladder cancer is a common malignancy of the urinary tract that is associated with about 16,840 estimated deaths in 2024. With the recent advances in bladder cancer treatment, it is unknown whether the trends in hospitalization outcomes have changed over time. We evaluated the trends in hospitalization outcomes among patients with a diagnosis of bladder cancer. Methods: This is a retrospective longitudinal trends study using the Nationwide Inpatient Sample (NIS) database (2008-2021). We identified hospitalizations with bladder cancer using ICD-9 and ICD-10 codes. Multivariate logistic and linear regression models were used to examine the trends in mortality outcomes stratified by demographic subgroups (age, gender and race). Results: There were over a million (1,123,567) hospitalizations with bladder cancer between 2008 and 2019. 73.5% were males; The mean age of the patients was 73.5 years. There was an overall increase in mortality amidst admissions with bladder cancer, from 4.5% in 2008 to 4.9% in 2021 (adjusted odds ratio [aOR]: 1.01; P-trend = 0.010). In the age subgroup, elderly patients (≥65 years) had an increase in mortality (aOR: 1.007; P-trend = 0.028). The young adults (18 - 44 years) and middle-aged adults (45 - 64 years) had no significant change in mortality rate (P-trend = 0.31 and P-trend = 0.131 respectively). For gender subgroup analysis, worse mortality outcomes were seen for males (aOR:1.01; P-trend=0.001); females had similar mortality over the period (P-trend=0.53). Racial subgroup analysis showed increased mortality outcomes for non-Hispanic White patients (aOR:1.01; P-trend=0.03). Black (P-trend=0.77) and Hispanic (P-trend=0.46) patients had no significant change in mortality outcomes. Conclusions: There was an overall increase in hospital mortality outcomes for bladder cancer patients from 2008-2021. While treatment advances continue to show improvement in survival outcomes, efforts are needed to ensure that hospitalized patients with bladder cancer have improved mortality outcomes. Inpatient mortality trends of bladder cancer stratified by demographic subgroups. Adjusted Odds Ratio P-Trend 95% Confidence Interval Overall Mortality 1.01 0.010 1.002-1.014 Young adults (18 - 44 years) 1.03 0.31 0.971-1.099 Middle-aged adults (45 - 64 years) 1.01 0.131 0.997-1.024 Elderly patients (≥65 years) 1.01 0.028 1.001-1.014 Male 1.01 0.001 1.005-1.019 Female 1.0 0.53 0.986-1.007 Non-Hispanic White 1.01 0.03 1.001-1.015 Black 1.00 0.77 0.979-1.016 Hispanic 0.99 0.46 0.968-1.015
Updated follow up of a randomized, double-blinded phase II study of ketoconazole (keto), hydrocortisone (HC), and anti-PSMA antibody J591 labeled with 177Lu or 111In in patients (pts) with high-risk non-metastatic (met) castration-resistant prostate cancer (M0 CRPC).
172 Background: Up to 1/3 of pts develop biochemical relapse following primary therapy. Many are not cured with salvage local therapy, likely because of undetectable distant disease. PSMA is expressed on most PC and can be targeted by radiolabeled J591. 177 Lu is a predominantly β-emitting radionuclide and also has γ emission which allows imaging. 111 In is predominantly a γ emitter, also with some auger emission for therapy. Hormonal therapy is effective and may increase PSMA expression and radiosensitivity. In this DOD-funded study initiated in the pre-PSMA PET and AR signaling inhibitor era, we hypothesized that 177 Lu prolongs 18-month (mo) met-free survival (MFS) more than 111 In in pts with high risk, M0 CRPC when targeting PSMA via J591 in combo with keto and HC. Methods: Pts with high risk M0 CRPC (PSA DT < 8 mo and/or absolute PSA > 20 ng/mL) and serum testosterone < 50 ng/mL with no evidence of metastatic disease on CT/MRI and bone scan were eligible. Treatment included a minimum 4 week lead-in with keto 400 mg TID and HC 20 mg AM, 10 mg PM (continued until unacceptable toxicity or development of mets) and a single infusion of J591 with 2:1 randomization to 177 Lu (70 mCi/m 2 ) or 111 In (5 mCi) in double-blinded fashion. 55 randomized pts provides 80% power to detect a difference in 18-mo MFS with one-sided alpha of 10%. Secondary endpoints include median MFS, overall survival, PSA response, and toxicity. Results: 55 pts with median age 68 (range 52 - 88), 75% prostatectomy, 23% primary radiation, 2% primary ADT; 19% local salvage therapy. Median PSA doubling time 3 mo (range 0.87 – 7.85), median baseline PSA 8.0 (range 1-78). In this intent to treat analysis (7 patients censored by 18 months), 31% of patients were without mets with 177 Lu compared to only 6.7% with 111 In (p=0.078) at 18 mo; biochemical PFS was 18.67 vs 8.87 mo, favoring 177 Lu in analyses censoring start of new treatment. Confirmed > 50% PSA decline occurred in 82% with 177 Lu and 71% with 111 In. The median MFS of the total patient population was 20.93 (CI: 17.02-34.2) mo, median 22.47 (CI: 17.35 to 68.11) mo for 177 Lu vs 20.5 (9.23-NA) mo for 111 In, p=0.65. The median overall survival of the total patient population was 76.35 (CI: 65.64-115.29) mo, no difference between 177 Lu and 111 In, p=0.48. With a median follow up of 63.8 mo, no new long term safety signals were discovered. Conclusions: PSMA-targeted 177 Lu combined with secondary hormonal therapy improves 18-mo MFS compared to PSMA-targeted 111 In. In the context of the current era with PSMA PET, this approach supports the early use of PSMA-targeted radionuclide therapy in patients with low volume mCRPC. Clinical trial information: NCT00859781 .
Phase II trial of image-guided oligometastatectomy and radiation therapy in recurrent prostate cancer (SOAR).
38 Background: In a subset of patients with molecular-imaging defined recurrent oligometastatic prostate cancer (PCa), salvage oligometastatectomy with surgery and/or radiation may provide improved androgen deprivation therapy (ADT)-free survival. Methods: This is a phase II trial with oligorecurrent PCa after primary prostatectomy or radiation therapy detected on Axumin (n=11) or Prostate-Specific Membrane Antigen (PSMA) (n=9) positron emission tomography. Oligometastatic disease was defined as ≤ 10 total sites, either of lymph node (LN) only (Group A), bone only (Group B), or LN and bone (Group C). Surgical intervention for patients with LN disease included extended pelvic and/or retroperitoneal LN dissection, depending on the location of the LNs. Groups A and C received adjuvant IMRT without ADT if PSA response was ≥ 1/3 decrease but remained ≥ 0.2 ng/dL. The primary outcome was a reduction in PSA by ≥ 50% at 6 months. Secondary objectives included PSA progression free-survival (PSA-PFS), ADT-free survival, and safety. Results: We accrued a total of 20 patients. The median age was 65 years (IQR 61-70), 95% (19/20) had an ECOG of 0, and 10% (2/20) were Hispanic. All patients had a prior prostatectomy, after which 45% (9/20) received adjuvant/salvage RT, with 33% (3/9) including the pelvis/ prostate bed. 30% (6/20) had exposure to ADT before trial treatment. The median time from definitive prostate cancer treatment to trial treatment was 2.8 years (IQR: 0.9-6.0). Oligorecurrent disease occurred as lymph nodes only (18/20; 90%) or bony (2/20; 10%). Within Group A, one patient completed adjuvant RT. The average number of imaging-identified positive LNs was 1.8 (range 1-6). The primary endpoint of reduction in PSA by ≥ 50% at 6 months was 40% (95%CI 19-64%) (Table 1). The secondary endpoint of PSA-PFS at 12 months was 84.4% (95%CI 66.6-100%). ADT-free survival at 12-months was 71.4% (95% CI 52.7% - 96.6%). There were no Clavien Grade III-IV complications. Conclusions: Salvage treatment of oligometastatic disease after prostatectomy or radiation identified on molecular imaging is feasible and safe. Nearly half the cohort had a good response to salvage treatment, demonstrated by a ≥ 50% reduction in PSA at 6 months. Ongoing analyses include comparing imaging and pathology correlations, and comparing complete/ partial responders and treatment failure. Further research is needed to identify ideal candidates for salvage treatment. Clinical trial information: NCT03796767 . PSA progression-free survival at 6- and 12-months (PFS). Time Estimate 95% Confidence Interval 6 months 100% --- 12 months 84.4% 66.6-100%
Safety and efficacy of bladder preservation therapy for very high-risk non-muscle-invasive bladder cancer: A single-center, single-arm prospective study (CIP-1).
805 Background: Radical cystectomy (RC) is the standard treatment for muscle-invasive bladder cancer (MIBC) and very high-risk non–muscle-invasive bladder cancer (NMIBC). However, many patients are unwilling or unable to undergo this surgery. Therefore, maximal tumor resection with concurrent chemoradiotherapy is an option. However, it has not been investigated adequately in NMIBC being received BCG which is prone to unresponsive until now. The study aims to evaluate the safety and efficacy of the comprehensive treatment for very high-risk NMIBC. Methods: The study prospectively selected the patients from January 2019 to July 2023. Inclusion criteria: 1) urothelial carcinoma pathology; 2) age <80 years; 3) tumor is possible to maximal resection; 4) muscle layer invasion-free and mpMRI VI-RADS score of 1-4; 5) no metastasis showed by CT or MRI. Exclusion criteria: 1) anterior urethra invasion; 2) dysfunction in bladder; 3) lymph node and/or distant metastasis; 4) persistent hydronephrosis; 5) absolute contraindications to chemoradiotherapy. After maximal tumor resection, patients with gemcitabine plus cisplatin (GC) neoadjuvant chemotherapy (NAC) as an optional treatment, were concurrent bladder radiotherapy (50-64Gy) and low-dose paclitaxel (50 mg/m2, D1/week) plus cisplatin (20 mg/m2, D1-2/week) chemotherapy. Record the adverse reactions, assess the recurrence and metastasis, and follow-up continued until October 2024 or death. Results: The study included 14 males (93.3%) and 1 female (6.7%); median age 60 (44–78) years, median follow-up 25 (11–75) months. 9 cases (60.0%) were initial presentation and 6 cases (40.0%, including 3 cases of BCG failure) were recurrence. 1 case had pathological subtype or CIS, respectively (6.7%). 7 cases (46.7%) approached GC NAC. The grade ≥III adverse reactions occurred in 10 instances: 6 episodes of leukopenia, 4 cases of radiation proctitis. 1 patient being incomplete the course (1/15) underwent salvage cystectomy (after 5 months). 2 deaths (2/14) occurred: 1 case developed posterior urethral metastasis after 19 months, refused further treatment, and died at 25 months; other case died at 20 months due to unexplained acute liver failure. 4 cases (4/14) experienced bladder recurrence at 10, 15, 20, and 28 months (T1 stage, single, <3cm, treated by TURBT), respectively. Among these 4 recurrence cases, only 1 (14.3%, 1/7) received NAC, while 3 (42.9%, 3/7) not. Patients completed the comprehensive treatment (14/15) had 1-year recurrence-free rate of 92.9% (13/14), tumor-specific mortality of 7.1% (1/14), median duration of response 23 (11–75) months, and post-recurrence bladder preservation survival 15 (5–39) months. Conclusions: The comprehensive treatment strategy for very high-risk NMIBC is safe and feasible, and NAC may improve the recurrence-free rate. Clinical trial information: 2000029504.
Distinct effects of Na and heavy alkali (K, Rb) incorporation in Cu(In, Ga)Se2 solar cells
Density functional theory calculations are performed to explore the nature of the alkali incorporation in Cu(In, Ga)Se2 (CIGS) thin-film solar cells. It is revealed that all the alkalis (Na, K, Rb) prefer to accumulate in the surface region of the absorber with occupying Cu sites. A hole barrier can be introduced in the absorber surface region, and the electron barrier at CdS/CuInSe2 interface is nearly changed after alkali incorporation. Distinct effects of Na and heavier alkalis (K and Rb) are explored. Post-deposition treatment (PDT) with Na leads to form NaxCu1−xInSe2 in the near-surface region. While monoclinic KInSe2 (or RbInSe2) secondary phase tends to form at the surface during K (or Rb) PDT. The hole barrier introduced by Na PDT can be much lower than that in the case of heavy alkali PDT due to the limited Na solubility in NaxCu1−xInSe2. The improved VOC in CIGS solar cells by heavy alkali PDT is mainly attributed to the absence of interfacial states and the elimination of isolated InCu and VCu defects in the surface region.
Concrete crack detection using ridgelet neural network optimized by advanced human evolutionary optimization
Real-world use and outcomes of darolutamide (DARO), enzalutamide (ENZA), and apalutamide (APA) for nonmetastatic castration-resistant prostate cancer (nmCRPC): Race subgroup analysis.
158 Background: Comparative real-world (RW) data on androgen receptor inhibitor (ARI; DARO, ENZA, APA) use in nmCRPC are limited. DEAR-EXT (NCT06013475) compared the RW utilization, tolerability, and outcomes of all 3 ARIs. Here we present a race subgroup analysis, based on data from the Black and White patient (pt) cohorts. Methods: DEAR-EXT is a retrospective chart review cohort study of men aged ≥18 years in the Precision Point Specialty Analytics network of US urology practices who initiated ARI treatment for nmCRPC for the first time (index date 8/2019–3/2023). Pts were categorized into White and Black cohorts based on their self-reported race. Key endpoints were time to and reasons for initial ARI treatment discontinuation, and metastasis-free survival (defined as time from index date until progression to mCRPC or death). Descriptive statistics and time-to-event analyses were conducted using unadjusted KM estimates and Cox proportional hazards models adjusted for baseline characteristics (age, race, insurance coverage, index year, PSA, time from nmCRPC diagnosis, and Gleason score). Results: A total of 282 Black and 923 White pts were included, of whom 41% received DARO, 44% ENZA, and 15% APA, in both race cohorts. Baseline characteristics were well balanced across treatment arms within each race cohort, except Gleason score and index year. Duration of follow-up was consistent across treatment subgroups (25.5–28.6 months). In both cohorts, the proportion of pts who discontinued their initial ARI treatment was lower for DARO vs ENZA or APA (Black: 33%, 45%, 49%; White: 38%, 53%, 50%, respectively). Similarly, in both race cohorts, progression to mCRPC or death was less frequent for DARO than ENZA or APA (Black: 26%, 35%, 42%; White: 34%, 49%, 45%, respectively). In adjusted Cox regression models, the risk of discontinuation and the risk of mCRPC progression or death in the DARO group were consistently lower in Black and White pts compared with ENZA and APA (range of hazard ratios [HRs] 0.49–0.79), while the differences between ENZA and APA were much less pronounced (HRs 0.80–1.16; Table). The most common reasons for ARI discontinuation were adverse events and disease progression/death, both occurring less frequently in the DARO group. Conclusions: DEAR-EXT real-world data reinforce DARO as an effective, well-tolerated treatment for nmCRPC, demonstrating potentially greater clinical benefits vs ENZA and APA among Black and White pts. Clinical trial information: NCT06013475 . Adjusted HR (95% Cl) DARO vs ENZA DARO vs APA ENZA vs APA Black pts Risk of ARI discontinuation 0.62 (0.40–0.97) 0.49 (0.28–0.88) 0.80 (0.47–1.37) Risk of mCRPC or death 0.79 (0.47–1.31) 0.67 (0.35–1.28) 0.85 (0.47–1.55) White pts Risk of ARI discontinuation 0.68 (0.54–0.85) 0.72 (0.53–0.96) 1.05 (0.80–1.38) Risk of mCRPC or death 0.60 (0.47–0.75) 0.69 (0.51–0.94) 1.16 (0.87–1.55)
Efficacy and toxicity profile of antibody-drug conjugate (ADC) based combination therapy in patients with advanced urothelial carcinoma (aUC): A systematic review of clinical trials.
813 Background: ADCs have revolutionized the treatment landscape of aUC and are being evaluated as part of combination regimens with checkpoint inhibitors (CPI) or other ADCs. We sought to evaluate the efficacy and safety/tolerability profile of ADC-based combination therapy in aUC. Methods: We systematically searched the PubMed and Embase databases for published prospective clinical trials through July 2024. Peer-reviewed clinical trials evaluating ADCs as part of a combination regimen in aUC were included. We extracted safety and efficacy outcomes, including objective-response rate (ORR), any-grade adverse events (AEs), and grade ≥3 AEs. We excluded reviews, editorials, retrospective studies, and case reports. Two independent reviewers screened titles and abstracts for relevance, followed by a full-text review to confirm eligibility. Results: 627 evaluable patients from 5 prospective trials investigating enfortumab vedotin or sacituzumab govitecan were identified. Overall, we recorded an ORR of 66.2%. 366 patients across all studies experienced ≥ grade 3 AEs, for a risk rate (RR) of 58.4%. By using a random-effects model, the pooled RR for AEs (Grade≥3) was 61% (95% CI, 52%–69%; P=0.18; Table). The most common grade ≥3 AEs were neutropenia (RR 0.14 [95% CI 0.04- 0.40]), anemia (RR 0.10 [95% CI 0.03-0.30]), and maculopapular rash (RR 0.10 [95% CI 0.04-0.23]). Distribution of specific AEs varied significantly based on regimen, with a higher incidence of ≥grade 3 anemia, neutropenia, and diarrhea in SG-based combinations (SG+ EV and SG+ CPI). Conclusions: While ADC-based combination regimens show promising responses, they also have high rates of AEs in patients with aUC. Further clinical trials evaluating these combination regimens are crucial to further optimize the role of ADCs in this disease setting. Safety/tolerability profile for any grade and grade ≥3 AEs. Toxicity Any Grade Grade≥3 Risk rate, 95% CI Risk rate, 95% CI Anemia 0.31 [0.09; 0.66] 0.10 [0.03; 0.30] Neutropenia 0.24 [0.05; 0.65] 0.14 [0.04; 0.40] Diarrhea 0.51 [0.19; 0.82] 0.07 [0.02; 0.17] Peripheral sensory neuropathy 0.50 [0.47; 0.54] 0.03 [0.02; 0.05] Fatigue 0.45 [0.26; 0.65] 0.06 [0.03; 0.13] Maculopapular rash 0.36 [0.26; 0.47] 0.10 [0.04; 0.23]
Sarcopenia as a marker to assess the surveillance necessity after a 5-year cancer-free period in patients who undergo radical cystectomy: A multi-institutional retrospective study.
871 Background: Although continuous surveillance after a 5-year cancer-free period in patients with bladder cancer (BC) who undergo radical cystectomy (RC) is recommended, optimal candidates for continuous surveillance remain unclear. Sarcopenia is associated with unfavorable prognosis in various malignancies. Thus, we hypothesized that sarcopenia, characterized by low muscle quantity, might be a useful marker to assess the necessity of surveillance after a 5-year cancer-free period in patients who underwent RC. Methods: This multi-institutional retrospective study included 274 patients with muscle-invasive bladder cancer (MIBC) who had a 5-year cancer-free period after RC. Muscle quantity was evaluated using the psoas muscle index (PMI) using computed tomography images five years after RC. The optimal cut-off values for all-cause mortality were calculated separately for men and women using receiver operating characteristic curves. Patients with lower PMI values than the cut-off values were diagnosed with sarcopenia. Recurrence-free survival (RFS) and overall survival (OS) after a 5-year cancer-free period were evaluated using the Kaplan–Meier method and compared using the log-rank test. Moreover, univariable and multivariable Cox proportional hazards regression analyses were performed to evaluate the impact of sarcopenia on OS. Results: The median age and follow-up period after the 5-year cancer-free period were 73 years and 63 months, respectively. Of the 274 patients, 129 (47%) were diagnosed with sarcopenia five years after RC. By the end of the follow-up period after the 5-year cancer-free period, 14 (5.1%) and 77 (28%) patients experienced recurrence and died from any cause, respectively. The 10-year RFS rate was 93%. RFS was not significantly different between the two groups, whereas OS in the sarcopenia group was significantly shorter than that in the non-sarcopenia group. After adjustment for confounding variables, sarcopenia was significantly associated with shorter OS (Table). Conclusions: Patients with sarcopenia might not need continuous surveillance after a 5-year cancer-free period, considering the high mortality rate. Multivariable analysis for OS. Factor P value Hazard ratio 95% CI Age Continuous <0.001 1.065 1.027–1.105 Performance status Continuous 0.012 1.829 1.145–2.922 Hypertension Positive 0.011 1.897 1.157–3.110 eGFR Continuous 0.168 0.990 0.976–1.004 Urinary diversion Neobladder 0.033 0.546 0.313–0.953 Sarcopenia Positive 0.025 1.801 1.076–3.012
Expanded access program of cretostimogene grenadenorepvec in patients with non-muscle invasive bladder cancer unresponsive to bacillus Calmette-Guerin.
TPS902 Background: The current American Urological Association (AUA) guideline recommendation for patients diagnosed with High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (HR BCG-UR NMIBC) is radical cystectomy. However, many patients are unwilling to undergo such a morbid intervention or are unfit due to competing medical risks. Therefore, a considerable unmet medical need exists for clinically effective, well-tolerated, and readily available bladder-sparing treatment options for patients with HR BCG-UR NMIBC. Cretostimogene grenadenorepvec is an oncolytic immunotherapy with a dual mechanism of action. It selectively replicates and lyses bladder cancer cells with Retinoblastoma (Rb)-E2F pathway alterations. The subsequent release of virus- and tumor- specific antigens initiate antitumor immune activation amplified by the GM-CSF transgene, a potent cytokine. Based upon preliminary efficacy and safety results from the ongoing Phase 3 BOND-003 study, cretostimogene received both Fast Track and Breakthrough Therapy Designations by the US FDA for BCG-UR NMIBC with CIS indication. The cretostimogene Expanded Access Program (EAP) ( NCT06443944 ) is an open-label, compassionate use clinical trial designed to provide cretostimogene to a diverse population of real-world patients with BCG-UR NMIBC with CIS who may not otherwise be eligible for currently enrolling clinical trials. Methods: Pragmatic real-world eligibility criteria include: age ≥18 years, ECOG performance status of 0-3, pathologically confirmed BCG-UR CIS +/- HG Ta/T1 disease after completion of adequate BCG treatment, as defined by the US FDA. Patients will receive intravesical cretostimogene in combination with n-dodecyl-β-D-maltoside (DDM), an excipient, that enhances adenoviral delivery for six weekly doses during the induction phase, followed by three weekly maintenance cycles quarterly through Month 12, then every six months through Month 24. Re-induction is permitted. Primary disease assessments include serial cystoscopy, urine cytology, axial imaging, and directed bladder biopsies as clinically indicated with local review of pathologic samples. The primary objective is to evaluate the safety of cretostimogene. The incidence of adverse events will be reported using Medical Dictionary for Regulatory Activities (MedDRA) and CTCAE v5.0. Secondary outcomes include Complete Response at any time and at 12 months, Duration of Response, high-grade Recurrence-Free Survival, Progression-Free Survival, and Radical Cystectomy-Free Survival. Exploratory outcome measures include Health-Related Quality of Life, Overall Survival, and biomarker assessments. A broad cross-section of geographically and socioeconomically diverse clinical sites have been identified. The study is open and actively recruiting. Clinical trial information: NCT06443944 .
Stacking-dependent tunable valley splitting in Janus SMoSiN2-based van der Waals heterostructure
Using the first principles calculation, we explore the modulation of valley-related properties of two-dimensional (2D) Janus SMoSiN2 monolayer by constructing van der Waals (vdW) heterostructure with the ferromagnet CrCl3 monolayer. The monolayered SMoSiN2 possesses excellent stability and direct bandgap at the K/K′ valley, making it a promising candidate for valleytronic semiconductor. The ferromagnet CrCl3 substrate induces a sizable valley splitting via proximity coupling. The valley-contrasting property of the top-stacking is significantly tunable by both in-plane sliding and vertical strain engineering, leading to extraordinary tunability of valley splitting in the range 1.6–9.4 meV. In contrast, the valley-contrasting property of the bottom-stacking is comparably robust due to the screen effect originating from the outmost N sublayer to reduce the proximity interaction. Our investigation reveals that the stacking order is a degree of freedom to manipulate the valley-related properties of various vdW heterostructures, facilitating the achievement of versatile valley-contrasting properties.
Grass pea dual purpose dry matter and seed yields in rainfed conditions across diverse environments
Modulation of enhancer of zeste homolog 2 (EZH2) pharmacodynamic markers and tumor gene expression by mevrometostat (PF-06821497) in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC).
146 Background: Mevrometostat (PF-06821497; M) is a potent and selective small molecule inhibitor of EZH2. Dose exploration of M in combination with enzalutamide (E) showed a manageable safety profile and promising activity in patients with mCRPC in a phase 1 study (NCT03460977). M exhibited dose-dependent pharmacokinetic (PK) exposure increases up to 1250 mg BID in combination with E (160 mg daily). We report the corresponding pharmacodynamic (PD) effects of EZH2 inhibition and tumor gene expression changes by M+E in patients with mCRPC. Methods: Serial whole blood and paired tumor biopsy samples were collected during dose escalation of M from 150 to 1250 mg BID in combination with E (160 mg QD) given on empty stomach in patients with mCRPC. Paired tumor biopsy samples were collected before the study and after 21 days of M+E or E. H3K27Me3 PD marker was evaluated in peripheral granulocytes by flow cytometry and in paired tumor biopsy samples by an immunohistochemistry assay. Tumor gene expression was profiled by whole transcriptomic RNA sequencing. Pre- and post-treatment sample gene expression levels and gene signature Gene Set Variation Analysis (GSVA) enrichment scores were analyzed by a simple linear model with transformation, if appropriate. Results: Dose-dependent H3K27Me3 PD marker reduction was observed in peripheral granulocytes and paired tumor biopsies by M+E in patients with mCRPC. Strong H3K27Me3 reduction (≥75%) in granulocytes was achieved at ≥375 mg of M+E. Tumor H3K27Me3 levels were effectively reduced from baseline in 6 patients receiving M at 1250 mg +E with a group mean change of –67% determined by H scores (95% CI: –86%, –23%; P =0.020) and –75% determined by H3K27Me3 staining (positive cells with high and medium intensity in tumor area) (95% CI: –93%, –11%; P =0.038). No significant change in tumor H3K27Me3 levels was observed in 4 patients receiving M at 500 mg +E. Consistent with strong EZH2 inhibition observed in tumor samples from patients receiving M at 1250 mg +E, M+E increased the expression of genes reported to be repressed by the PRC2/EZH2 complex (e.g., BMP7 , CPAMD8 , EYA4 , FHL1 , IGFBP3 and NOV ), and decreased expression of EZH2 and other genes involved in the E2F pathway, the G2M checkpoint, Myc responsive genes and/or cell cycle progression (e.g., AURKA , CDK1 , FOXM1 , RAD54L , TOP2A and TYMS ). Conclusions: These data indicate M at 1250 mg BID on empty stomach in combination with E effectively inhibits EZH2 in tumor tissue and may overcome drug resistance and/or enhance androgen targeting drug activity by restoring the function of tumor suppressor genes and blocking tumor cell proliferation and cell cycle progression. These data support dose recommendation for phase 3 pivotal studies and enhance understanding of mechanism of action for M+E in mCRPC. Clinical trial information: NCT03460977 .
Enfortumab vedotin plus pembrolizumab in metastatic urothelial carcinoma: First results on outcomes and safety in a German multicenter real-world patient cohort (GUARDIANS).
715 Background: The prospective phase 3 study EV-302 demonstrated superiority regarding efficacy of Enfortumab vedotin plus Pembrolizumab (EVP) compared to platinum-based chemotherapy in patients (pts) that received first-line (1L) therapy for metastatic urothelial carcinoma (mUC). Since presentation of the data in September 2023 EVP was considered a new standard of care (SOC) however only approved in Europe in August 2024. We analyzed efficacy and safety outcomes of pts treated with EVP outside of clinical trials. Methods: Retrospective data were collected from 19 German academic and community hospitals for pts with metastatic UC who received EVP as off-label therapy when reimbursed by their insurance company before European Medicines Agency (EMA) approval, or as SOC treatment after EMA approval. Imaging and therapy management were in accordance with local standards. Adverse events (AEs) were reported according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 criteria. Median progression-free survival (mPFS) and overall survival (mOS) were estimated using the Kaplan-Meier method by local investigators. Results: We identified 215 pts for the safety cohort (all pts who received EVP at least once) and 164 pts for the efficacy cohort (all pts who received at least one staging or died prior to first planned imaging).The median age for the eligible patients was 71 yr (range 25-89). The Eastern Cooperative Oncology Group performance status (ECOG PS) was 0/1/2/3-4/unknown for 46.0/31.6/17.2/4.7/0.5% of patients. The overall response rate was 60.7% (partial response 51.0%, complete response 9.7%). mOS was not reached and mPFS was 13 mo (95% confidence interval 4.5-21.5). Any-grade AEs were observed in 73.0% and CTCAE grade ≥3 AEs in 30.2%. Any-grade immune-related AEs were observed in 37.7% and CTCAE grade ≥3 AEs in 16.7%. The most common AEs were peripheral sensory neuropathy (all grade: 30.2%) and skin toxicity (all grade:24.2%). No treatment-related fatal event occurred. Limitations include the retrospective design and short follow-up. Conclusions: Administration of EVP in a real-world patient population showed promising effectiveness and an acceptable toxicity profile. No new safety signals were reported. Our results support the use of EVP in 1L in pts with mUC. Updated data with longer follow-up will be presented at the meeting.
Phase 1b/2 study of combination <sup>177</sup> Lu girentuximab plus cabozantinib and nivolumab in treatment naive patients with advanced clear cell RCC.
TPS614 Background: Complete response (CR) is a rare event in advanced clear cell renal cell carcinoma (ccRCC). The combination of nivolumab plus cabozantinib was recently approved for first-line treatment of ccRCC, demonstrating improved progression-free survival (PFS) and objective response rate (ORR) in comparison to sunitinib. However, CR is only 9%. Drugs that could synergize with T cell anti-tumor activity can improve CR rates. Radiation-induced DNA damage to activate the cGAS-STING pathway is a promising mechanism. 177 Lu-girentuximab is the first antibody-radioisotope designed for ccRCC, targeting carbonic anhydrase 9, expressed in >90% ccRCC, to deliver targeted radiation to cancer with minimal damage to surrounding healthy cells. As a single agent in metastatic ccRCC, 177 Lu-girentuximab was safe and effective in stabilizing disease in 57% of patients. We hypothesize 177 Lu-girentuximab-induced DNA damage will potentiate the STING pathway, synergizing with nivolumab and cabozantinib to promote trafficking and infiltration of activated T cells and achieve higher CR rates. Methods: Up to 100 patients with treatment naive, biopsy-proven ccRCC with adequate organ/marrow function with 1 evaluable lesion by RECIST 1.1 will be enrolled. A 5-patient safety lead-in will evaluate myelosuppression. Ongoing safety and futility monitoring will employ a Bayesian approach. The sample size was chosen for reasonable operating characteristics to distinguish a CR rate (primary endpoint) of 18% as better than 9% using a beta (0.09, 0.91) prior. Secondary endpoints are ORR, PFS by RECIST 1.1, and overall survival. 177 Lu-girentuximab 1480 MBq/m 2 (61% of single agent MTD) will be administered every 12 weeks for up to 3 cycles. Starting with the second cycle, nivolumab and cabozantinib will be added at standard dose. To explore the effects of the treatment on inducing activated T cell infiltration, patients will undergo pre/post-treatment PET scan with 18 F-AraG radiotracer as well as biopsies for single cell, spatial transcriptomics, and proteomics studies. Clinical trial information: NCT05663710 .
Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Final follow-up results from the CheckMate 9ER trial.
439 Background: N+C showed significant benefits vs S in progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) for patients (pts) with previously untreated aRCC from the phase 3 CheckMate 9ER trial ( N Engl J Med 2021; 384:829–41). We report final results for the trial with a long-term follow-up (min, >5 y), including updated efficacy in intent-to-treat (ITT) pts and by International Metastatic RCC Database Consortium (IMDC) risk, and safety. Methods: Pts with aRCC were randomized to receive first-line N 240 mg every 2 wk + C 40 mg QD or S 50 mg QD (4 wk of each 6-wk cycle) until disease progression or unacceptable toxicity (2 y N max.). The primary endpoint was PFS per RECIST v1.1 by blinded independent central review (BICR). Secondary endpoints included OS, ORR per RECIST v1.1 by BICR, and safety. Results: Median follow-up was 67.6 (range, 60.2–80.2) mo. In ITT pts (N+C, n = 323; S, n = 328), PFS favored N+C vs S (hazard ratio [HR], 0.58 [95% CI, 0.49–0.70]). Median (95% CI) PFS (mPFS) was 16.4 (12.5–19.3) vs 8.3 (7.0–9.7) mo, respectively; 60-mo PFS rates were 13.6% vs 3.6%. OS also favored N+C vs S (HR, 0.79 [95% CI, 0.65–0.96]). Median (95% CI) OS (mOS) was 46.5 (40.6–53.8) vs 35.5 (29.2–42.8) mo, respectively; 60-mo OS rates were 40.9% vs 35.4%. ORR was greater with N+C vs S (55.7% vs 27.4%; complete response [CR], 13.9% vs 4.6%). Duration of response (DOR) rates at 60 mo with N+C vs S were 22.0% vs 10.0%, respectively. Efficacy by IMDC risk groups is reported in the Table. In all treated pts (n = 320 each arm), any-grade (grade ≥ 3) treatment-related adverse events occurred in 97.5% (67.8%) vs 93.1% (55.3%) with N+C vs S. No new deaths due to study drug toxicity occurred since the last database lock. Additional subgroup analyses will be presented. Conclusions: Long-term efficacy benefit was observed with N+C over S in this final follow-up from CheckMate 9ER. There were no new safety signals. The results continue to support N+C as a standard of care for previously untreated aRCC. Clinical trial information: NCT03141177 . FAVN+C; n = 74 FAVS; n = 72 INTN+C; n = 188 INTS; n = 188 PoorN+C; n = 61 PoorS; n = 68 PFS HR (95% CI) 0.67 (0.46–0.97) - 0.63 (0.50–0.80) - 0.36 (0.23–0.56) - mPFS (95% CI), mo 21.4 (12.8–24.6) 12.8 (9.4–16.6) 16.6 (11.3–21.7) 8.5 (6.9–10.4) 9.9 (5.9–17.7) 4.2 (2.9–5.7) 60-mo PFS rate, % 15.1 3.9 12.7 4.7 15.7 0 OS HR (95% CI) 1.08 (0.70–1.66) - 0.86 (0.67–1.11) - 0.49 (0.33–0.74) - mOS (95% CI), mo 53.7 (40.8–70.7) 58.9 (46.1–NE) 47.4 (38.2–55.8) 36.2 (25.7–46.3) 34.8 (21.4–53.4) 10.5 (6.8–20.7) 60-mo OS rate, % 46.3 49.4 41.2 38.2 33.1 12.9 ORR (95% CI), % 66.2 (54.3–76.8) 43.1 (31.4–55.3) 55.9 (48.4–63.1) 27.7 (21.4–34.6) 42.6 (30.0–55.9) 10.3 (4.2–20.1) CR, % 16.2 6.9 15.4 4.8 6.6 1.5 60-mo DOR rate, % a 22.0 NE 19.0 13.0 37.0 0 FAV, IMDC favorable; INT, IMDC intermediate; NE, not estimable; poor, IMDC poor. a Based on pts with objective response.